Grants for Native American tribal organizations - Health

This grant provides funding for innovative research using invasive brain recording and stimulation techniques in humans to improve understanding of the neural circuits involved in mental health disorders.

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. NINDS is committed to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. See the Notice of NIH

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

This funding opportunity provides financial support to Tribal communities to strengthen their systems for preventing and addressing elder abuse, neglect, and exploitation among American Indian, Alaska Native, and Native Hawaiian populations.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

The purpose of this Negotiation Cooperative Agreement is to provide Tribes with resources to help defray the costs associated with preparing for and engaging in TSGP negotiations. TSGP negotiations are a dynamic, evolving, and tribally driven process that requires careful planning, preparation, and sharing of precise, up-to-date information by both Tribal and Federal parties. Because each Tribal situation is unique, a Tribes successful transition into the TSGP, or expansion of their current program, requires focused discussions between the Federal and Tribal negotiation teams about the Tribes specific health care concerns and plans. One of the hallmarks of the TSGP is the collaborative nature of the negotiations process, which is designed to: 1) enable a Tribe to set its own priorities when assuming responsibility for IHS PSFAs; 2) observe and respect the government-to-government relationship between the U.S. and each Tribe; and 3) involve the active participation of both Tribal and IHS representatives, including the OTSG. Negotiations are a method of determining and agreeing upon the terms and provisions of a Tribes Compact and FA, the implementation documents required for the Tribe to enter into the TSGP. The Compact sets forth the general terms of the government-to-government relationship between the Tribe and the Secretary of the U.S. Department of Health and Human Services (HHS). The FA: 1) describes the length of the agreement (whether it will be annual or multi-year); 2) identifies the PSFAs, or portions thereof, the Tribe will assume; 3) specifies the amount of funding associated with the Tribal assumption; and 4) includes terms required by Federal statutes and other terms agreed to by the parties. Both documents are required to participate in the TSGP and they are mutually negotiated agreements that become legally binding and mutually enforceable after both parties sign the documents. Either document can be renegotiated at the request of the Tribe.

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.

This funding opportunity supports researchers in developing innovative tools to measure human behavior and synchronize these measurements with brain activity, aiming to advance our understanding of brain-behavior relationships and improve interventions for neurobehavioral conditions.

This funding opportunity is designed to support the establishment of collaborative research centers that enhance the study and treatment of bone, muscle, and orthopaedic conditions through shared resources and multidisciplinary approaches.

This funding opportunity supports researchers in analyzing existing oral health data or developing new statistical methods to improve data analysis, with a focus on establishing causal relationships rather than just identifying correlations.

The "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD" grant aims to fund innovative research strategies that use advanced tools to target and manipulate specific brain cells affected by aging, Alzheimer's Disease, and related dementias, in order to better understand these conditions and their impact on brain function.

This funding opportunity supports innovative research on how communication between mitochondria and the nucleus affects Alzheimer’s Disease and related dementias, inviting applications from universities, nonprofits, and other organizations.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UM2 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support to higher education institutions and tribal organizations to develop or expand maternal and child health training programs, aiming to strengthen the workforce in this critical public health area.

This ISO seeks solution summary and proposal submissions for projects that fall within the scope of the ARPA-H mission Resilient Systems Office (RSO). RSOs interest areas will address systemic challenges across the healthcare and public health landscape by investing in cutting-edge technologies that address long-standing gaps in the quality, efficacy, and consistent availability of care.Aspects of todays health and public health systems remain fragile due to systemic challenges, which include rising healthcare costs, inadequate healthcare coverage for significant populations, outdated infrastructure, and health disparities among different demographic groups. Acute challenges, such as hospital closures, supply chain disruptions, staffing shortages, cyber-attacks, public health crises, and the emergence of new diseases, further exacerbate existing fragilities, making it more difficult to maintain high standards of care. These challenges are compounded by the fact that systems remain fragmented, hindering the ability to gain comprehensive insights, make informed decisions, develop tailored interventions, and share critical health information between stakeholders.RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. Of interest are innovations that foster flexibility and enable adaptation to system stressors, so that people and systems remain well-positioned to deliver high-quality care and improve health outcomes. The following interest areas categorize the ground-breaking research we seek to support:Sociotechnical System Innovation: Innovate user-centric digital health tools, platforms, technologies, and intervention models that improve outcomes across the health continuum, including prevention, diagnosis, and treatment of physical, mental, and behavioral health. Approaches to build trust in the healthcare system and distribute high-quality health guidance in an understandable manner that improves patient outcomes. Novel real-time measurement tools to track health outcomes, evaluate post-market performance of new interventions, and enable convergence on the most effective strategies to improve the quality of care, especially for underserved communities. Other population centered innovations to create more resilient communities and subpopulations. Innovations might include aggregate improvements to quality of care and better physical, mental, and behavioral health outcomes for the health ecosystem.Health Ecosystem Integration: Novel ways to collect, protect, secure, integrate, analyze, communicate, and present health data, including but not limited to advances in privacy, cyber security, artificial intelligence with enhanced patient safety properties, low-code or no-code technologies, semantic approaches, and rapid integration techniques. Strategies and technologies to leverage homes, community centers, pharmacies, and other accessible locations to enable new modalities of high-quality care, expand the reach of clinical research, or integrate end-user feedback to rapidly iterate prototype designs. Approaches to strengthen the connectivity and interoperability of health data and devices to 5 enable the safe, secure, and seamless exchange of information among healthcare providers, researchers, and stakeholders. Other novel approaches to increase the interoperability of health-related systems in support of improved health outcomes and enhanced transparency across the health ecosystem.Adaptive Antifragile Solutions: Creative approaches to enhance the stability and dependability of the health ecosystem through new adaptive paradigms, methods that anticipate and mitigate disruptions before they occur, and enhancements to emergency response. Approaches that enable health infrastructure to rapidly integrate information from new sensors; create decision support tools; adapt supply chains, manufacturing, and logistics; and better leverage the workforce during public health emergencies. Novel methods to engineer resilient tissues, microbiomes, and biophysical systems to combat disease or maintain health. Other novel approaches to enhance adaptability and reduce fragility within the health ecosystem.Proposals are expected to use innovative approaches to enable revolutionary advances in science, technology, systems, or methodology. Specifically excluded are proposals that represent an evolutionary or incremental advance in the state of the art or technology that has reached the clinical trial stage. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission

This funding opportunity supports U.S.-based institutions in planning and implementing clinical trials aimed at improving treatments for dental, oral, and craniofacial conditions.

This funding opportunity provides financial support to organizations focused on improving mental health and care engagement for individuals living with HIV, particularly those facing barriers to treatment.